Drugs Made in America Delays Annual Filing

Drugs Made In America Acquisition Corp. ( (DMAA) ) has released a notification of late filing.

Drugs Made in America Acquisition Corp. has filed a Form 12b-25 to notify investors of a delayed Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company says it could not complete all required financial statements and related disclosures in time for its Annual Report on Form 10-K (Yearly Report).

Management cites the need to compile financial information as the main driver of the delay, indicating that filing on time would have required unreasonable effort or expense. There is no mention of auditor changes, control failures, or special committee reviews in connection with this delay.

The company has committed to filing the overdue Annual Report on Form 10-K (Yearly Report) on or before April 15, 2026. Under SEC rules, Form 12b-25 provides an automatic grace period, and the firm has indicated it will use this extended deadline.

Drugs Made in America Acquisition Corp. does not expect any significant changes in its results of operations versus the prior fiscal year once the Form 10-K (Yearly Report) is filed. Investors should remember that these expectations are forward-looking and could change once the full audited financials and disclosures are available.

The company states that all other required SEC reports over the past 12 months have been filed, signaling ongoing baseline compliance. The notification was signed on April 1, 2026, by Chief Executive Officer Roger E. Bendelac, underscoring management’s responsibility for the delayed filing and its plan to complete the report promptly.

More about Drugs Made In America Acquisition Corp.

Average Trading Volume: 82,421

Technical Sentiment Signal: Strong Buy

Current Market Cap: $351.8M

See more data about DMAA stock on TipRanks’ Stock Analysis page.